Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Bought by GF Fund Management CO. LTD.

GF Fund Management CO. LTD. boosted its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 1.8% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 75,636 shares of the medical equipment provider's stock after purchasing an additional 1,305 shares during the period. Intuitive Surgical makes up approximately 0.9% of GF Fund Management CO. LTD.'s holdings, making the stock its 20th largest position. GF Fund Management CO. LTD.'s holdings in Intuitive Surgical were worth $37,460,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in ISRG. OneDigital Investment Advisors LLC grew its position in shares of Intuitive Surgical by 3.9% during the 1st quarter. OneDigital Investment Advisors LLC now owns 15,535 shares of the medical equipment provider's stock valued at $7,694,000 after acquiring an additional 588 shares during the period. 44 Wealth Management LLC grew its position in shares of Intuitive Surgical by 3.9% during the 1st quarter. 44 Wealth Management LLC now owns 1,112 shares of the medical equipment provider's stock valued at $551,000 after acquiring an additional 42 shares during the period. Fisher Funds Management LTD grew its position in shares of Intuitive Surgical by 22.5% during the 1st quarter. Fisher Funds Management LTD now owns 203,604 shares of the medical equipment provider's stock valued at $100,839,000 after acquiring an additional 37,446 shares during the period. Avantax Planning Partners Inc. grew its position in shares of Intuitive Surgical by 9.6% during the 1st quarter. Avantax Planning Partners Inc. now owns 1,152 shares of the medical equipment provider's stock valued at $571,000 after acquiring an additional 101 shares during the period. Finally, Silver Oak Securities Incorporated grew its position in shares of Intuitive Surgical by 17.5% during the 1st quarter. Silver Oak Securities Incorporated now owns 2,097 shares of the medical equipment provider's stock valued at $1,031,000 after acquiring an additional 313 shares during the period. Institutional investors own 83.64% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Robert W. Baird cut their price objective on shares of Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating for the company in a research report on Wednesday, April 23rd. Erste Group Bank upgraded shares of Intuitive Surgical from a "hold" rating to a "buy" rating in a research note on Thursday, June 5th. Evercore ISI lowered their target price on shares of Intuitive Surgical from $510.00 to $470.00 and set an "in-line" rating on the stock in a research note on Wednesday, April 23rd. Piper Sandler lowered their target price on shares of Intuitive Surgical from $670.00 to $575.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 23rd. Finally, BTIG Research set a $560.00 target price on shares of Intuitive Surgical and gave the company a "buy" rating in a research note on Monday, April 14th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat, Intuitive Surgical has a consensus rating of "Moderate Buy" and a consensus price target of $588.95.

Insider Buying and Selling at Intuitive Surgical

In other news, SVP Mark Brosius sold 216 shares of the stock in a transaction that occurred on Friday, June 6th. The shares were sold at an average price of $563.11, for a total transaction of $121,631.76. Following the transaction, the senior vice president directly owned 907 shares in the company, valued at approximately $510,740.77. This trade represents a 19.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Gary Loeb sold 1,700 shares of the stock in a transaction that occurred on Friday, April 25th. The shares were sold at an average price of $513.18, for a total transaction of $872,406.00. Following the transaction, the executive vice president owned 2,245 shares in the company, valued at approximately $1,152,089.10. This represents a 43.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 4,998 shares of company stock valued at $2,611,577 in the last ninety days. Company insiders own 0.70% of the company's stock.

Intuitive Surgical Price Performance

ISRG stock traded down $7.71 during mid-day trading on Monday, reaching $536.76. The company had a trading volume of 349,661 shares, compared to its average volume of 1,667,715. The company has a market capitalization of $192.39 billion, a PE ratio of 78.70, a price-to-earnings-growth ratio of 5.78 and a beta of 1.64. The firm has a 50 day moving average of $537.11 and a 200 day moving average of $536.92. Intuitive Surgical, Inc. has a 12 month low of $413.82 and a 12 month high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.71 by $0.10. The business had revenue of $2.25 billion for the quarter, compared to the consensus estimate of $2.19 billion. Intuitive Surgical had a net margin of 28.41% and a return on equity of 14.43%. During the same period in the prior year, the firm earned $1.50 EPS. Analysts anticipate that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.